Want to join the conversation?
Global pharmaceutical giant $ABBV announced that its product candidate for treatment of rheumatoid arthritis, selective JAK1 inhibitor ABT-494, has successfully achieved its primary endpoint in two Phase 2 studies."We are encouraged by Phase 2 results & we'll advance ABT-494 to Phase 3 studies with once-daily formulation," said Mike, EVP R&D & CSO.
$SBUX launched its annual “Starbucks for Life” competition in the U.S. and Canada. The winner of the competition will receive a credit of one drink or food item per day for a duration of 30 years.
$T shares rose 1.8%, as a big boost for the S&P 500. The company said its new streaming television service DirectTV has so far exceeded expectations.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.